Real-World Data: FDA Urged To Distinguish Between Electronic Health Records And Medical Claims

Comments on September draft guidance seek more attention to differences between the two types of data sources; pharma firms said they may not always have access to all the information the US FDA wants to see about a particular data source, and they seek additional flexibility on validation.

Yellow and red
Pharma and data companies want the FDA to better distinguish between electronic health records and claims data in a real-world data guidance. • Source: Alamy

The US Food and Drug Administration’s recent guidance on assessing electronic health records and claims databases to support regulatory decision-making should better distinguish between these two types of real-world data sources, stakeholders said.

More from Real-World Evidence

UK’s MHRA To Offer Private Meetings For Innovative RWE Strategies

 

The MHRA’s new scientific dialog program will offer drug developers “closed-door meetings” that will offer “confidential, commercially sensitive discussion” with its staff to help them “refine” their real-world evidence generation strategies.

Postmarket Studies A Good Fit For Pragmatic And Decentralized Elements

 
• By 

Incorporating pragmatic and decentralized approaches into postapproval studies presents less risk for data collection and reliability than in the premarket setting, an expert panel said at a Friends of Cancer Research meeting.

US FDA’s RWE Efforts Gain ‘Focal Point’ With New CDER Center

 

The Center for Real-World Evidence Innovation will promote consistency across the FDA drug center’s many initiatives while addressing regulatory and scientific barriers to real-world evidence in regulatory decisions.

Real-World Evidence Helps Open Accelerated Approval Pathway For Neurodegeneration Therapies

 

Clene’s ALS drug CNM-Au8 and UniQure’s gene therapy for Huntington’s disease emerged from US FDA discussions with accelerated approval plans using real-world evidence from compassionate use and natural history data sources.

More from Clinical Trials

US FDA Guidance Redefines Obesity, But Keeps 2007 Efficacy Standard

 

The US Food and Drug Administration updated obesity drug development draft guidance for the first time in almost 20 years and although a lot has changed in the field, the FDA’s fundamental expectations to support approval did not.

Science and Politics May Collide As US FDA Offers More Precise Definitions Of Sex And Gender

 

The draft guidance clarifies that sex and gender are not interchangeable, but could be vulnerable in the Trump Administration as Republicans have argued against transgender medical care and that sex and gender must be congruent.

Off-Label Communications: US FDA Clarifies Safe Harbor For Firm-Generated Presentations

 
• By 

Final guidance on communicating scientific information on unapproved uses (SIUU) allows firm-generated presentations to be based on sources other than reprints, but says communications based on nonscientific content are not protected from enforcement.